Related Experiment Video
Updated: May 5, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Reverse yeast two-hybrid system to identify mammalian nuclear receptor residues that interact with ligands and/or
Hao Li1, Wei Dou, Emil Padikkala
1Department of Genetics, Albert Einstein College of Medicine.
Abstract:
As a critical regulator of drug metabolism and inflammation, Pregnane X Receptor (PXR), plays an important role in disease pathophysiology linking metabolism and inflammation (e.g. hepatic steatosis)(1,2). There has been much progress in the identification of agonist ligands for PXR, however, there are limited descriptions of drug-like antagonists and their binding sites on PXR(3,4,5). A critical barrier has been the inability to efficiently purify full-length protein for structural studies with antagonists despite the fact that PXR was cloned and characterized in 1998. Our laboratory developed a novel high throughput yeast based two-hybrid assay to define an antagonist, ketoconazole's, binding residues on PXR(6). Our method involves creating mutational libraries that would rescue the effect of single mutations on the AF-2 surface of PXR expected to interact with ketoconazole. Rescue or "gain-of-function" second mutations can be made such that conclusions regarding the genetic interaction of ketoconazole and the surface residue(s) on PXR are feasible. Thus, we developed a high throughput two-hybrid yeast screen of PXR mutants interacting with its coactivator, SRC-1. Using this approach, in which the yeast was modified to accommodate the study of the antifungal drug, ketoconazole, we could demonstrate specific mutations on PXR enriched in clones unable to bind to ketoconazole. By reverse logic, we conclude that the original residues are direct interaction residues with ketoconazole. This assay represents a novel, tractable genetic assay to screen for antagonist binding sites on nuclear receptor surfaces. This assay could be applied to any drug regardless of its cytotoxic potential to yeast as well as to cellular protein(s) that cannot be studied using standard structural biology or proteomic based methods. Potential pitfalls include interpretation of data (complementary methods useful), reliance on single Y2H method, expertise in handling yeast or performing yeast two-hybrid assays, and assay optimization.
Insights
Researchers developed a novel yeast-based assay to identify antagonist binding sites on the Pregnane X Receptor (PXR). This method successfully mapped ketoconazole
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Pregnane X Receptor (PXR) is a key regulator of drug metabolism and inflammation, implicated in diseases like hepatic steatosis.
- Identifying PXR antagonists and their binding sites is crucial, but challenging due to difficulties in protein purification for structural studies.
- Existing research has focused on PXR agonists, with limited understanding of antagonist interactions.
Purpose of the Study:
- To develop a novel, high-throughput assay for identifying antagonist binding sites on PXR.
- To map the specific binding residues of the antifungal drug ketoconazole on PXR.
- To establish a versatile genetic method applicable to various drugs and challenging protein targets.
Main Methods:
- Development of a high-throughput yeast-based two-hybrid assay.
- Creation of mutational libraries targeting the AF-2 surface of PXR.
- Screening PXR mutants for interaction with coactivator SRC-1 in the presence of ketoconazole.
Main Results:
- The assay successfully identified specific PXR mutations that abolish ketoconazole binding.
- By reverse logic, these mutations pinpoint the direct interaction residues for ketoconazole on PXR.
- The method demonstrated efficacy in studying ketoconazole's interaction with PXR.
Conclusions:
- A novel and tractable yeast two-hybrid assay was established for screening antagonist binding sites on nuclear receptors.
- This genetic assay overcomes limitations of traditional structural biology and proteomics methods.
- The assay is broadly applicable to diverse drugs and proteins, including those with cytotoxic potential or difficult purification.
More Related Videos
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
12:43Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study
Published on: July 27, 2016
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...